Dan Jiang
Chongqing Medical University
6 Papers
Dan Jiang is an academic researcher from Chongqing Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
137P Tislelizumab combined with chemotherapy as neoadjuvant therapy for stage IIIA-IIIB(N2) potentially resectable squamous non-small-cell lung cancer (TACT)
Jiqi Shan,Z. Liu,C. Du,Y Hu,Lingling Ruan,X. Teng,L. Wang,Miaoyan Du,T. Tian,Dan Jiang,Zachary H. Tu +10 more
TL;DR: TACT (NCT05024266) is a phase II, open label, single arm trial evaluating the efficacy and safety of tislelizumab(Tis) plus chemotherapy(CT) as neoadjuvant treatment for potentially resectable stage IIIA-IIIB(N2) squamous NSCLC as mentioned in this paper .
2
Correction to: SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway
Jing Zhang,Xiaohan Liu,Cong Li,Xiao-xing Wu,Yanlin Chen,Wen-wen Li,Xian Li,Fan Gong,Qin Tang,Dan Jiang +9 more
TL;DR: An amendment to this paper has been published and can be accessed via the original article.
Genetic Analysis and Combined Therapy of Surgery and Chemotherapy for the Progression-Free Survival of a Patient with Ovarian Carcinosarcoma: A Case Report and Literature Review
TL;DR: The disease was diagnosed in the early stage, and the use of a R0 resection + a three-drug combination chemotherapy may have contributed to the patient’s long-term disease-free survival, speculated that the origin of this case may have been the fallopian tube.
3P Beyond first-line therapy in metastatic adrenal cortical cancer (ACC): Is it time to move on from chemotherapy?
A. Mittal,Lama Amer,O. Ayodele,S Radi,X. Li,Ozgur Mete,J Pasternak,Dan Jiang,V. Kumar,Aaron R. Hansen +9 more
TL;DR: In this paper , a retrospective review of metastatic cancer patients treated at Princess Margaret Cancer Center was performed, where patients who received any 2nd-line therapy and beyond were identified.
SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway.
Jing Zhang,Xiaohan Liu,Cong Li,Xiao-xing Wu,Yanlin Chen,Wen-wen Li,Xian Li,Fan Gong,Qin Tang,Dan Jiang +9 more
TL;DR: SNCG up-regulation contributes to the poor clinical outcome of patients with HGSOC and highlight the metastasis-promoting function of SNCG via activating the PI3K/Akt signaling pathway in H GSOC.